As part of Avara’s Business Continuity actions, our goal is to support the delivery of all key project milestones, in order to minimize impact from Coronavirus (Covid-19) prevention measures. Where current restrictions may prevent a site visit or audit of Avara’s facilities, we are happy to offer you a “virtual visit or audit” experience to enable your program to move forward. Please email us at firstname.lastname@example.org or contact your dedicated Business Development team member to discuss details of this program and how it can help fulfill your project needs.
Mar 18, 2020 1:44:13 PM
Feb 12, 2020 9:10:31 AM
In 2019, Avara refocused the business on its core capabilities within Oral Solid Dose and Sterile and this resulted in an annual EBITDA of $30.7M (unaudited), at 15% on revenues of $203M, with positive contributions from every Avara facility.
During the year, Avara committed significant investment to its facilities to further enhance capabilities, including; the ability to handle bi-/tri-layer tablet compression; hot melt technology; increased encapsulation capacity; automated visual inspection; and obtaining DEA licensing to support Schedule II and III controlled drug products. All regulatory inspections and client audits were 100% successfully completed.
In 2020, the group is committed to work relentlessly to serve its clients, invest in its people and in new capabilities, and pursue its strategy of organic growth and selective acquisition.
Jan 21, 2020 12:27:06 PM
Avara’s Liscate facility provides sterile manufacturing, fill-finish, and packaging services for supply to European, United States, Canadian, and Latin American markets. During Q4 2019, the facility hosted the US FDA as part of a Pre-Approval Inspection for a new Client’s product to be manufactured in the Small Volume Parenterals department. In addition, a routine GMP inspection for the Lyophilization department was conducted. We were delighted that the US FDA Inspector has acknowledged the high standards and experience in Avara Liscate by recommending the renewal of the license and approval of the new product. Along with approvals also received for AIFA, ANVISA and MFDS Korea, this completes a successful year of regulatory inspections for Avara Liscate.
Also, Avara Liscate is excited to announce the appointment of a new Manufacturing Director to the leadership team. Vincenzo Riello joins the Avara Liscate team on January 7th, 2020 and brings with him a wealth of experience in sterile manufacturing gained over many years in large pharma organizations as well as CDMOs. Marco Scanziani, who held the position prior, will be Avara Liscate’s new Customer Relationship Leader and will apply his 15 years of manufacturing and quality experience to leading the Project Management function in Avara Liscate.
Avara Liscate, and indeed the whole Avara group, is excited to welcome the New Year and decade and look forward to continuing to support and collaborate with our existing and new Clients.